Authors : Dr. N. Meher Satya Vani

Volume/Issue : Volume 9 - 2024, Issue 9 - September

Google Scholar : https://tinyurl.com/255jbb9n

Scribd : https://tinyurl.com/bddz3kxs

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP1097

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Myocarditis is a rare but key adverse event linked to mRNA COVID-19 vaccines, predominantly in young males. Epidemiological data indicate an incidence of approximately 12.6 cases per million doses administered to patients aged 12-39 years, mostly following the second dose of the vaccine. Most patients present with elevated levels of cardiac biomarkers, chest pain, and abnormal ECG findings within a few days of vaccination. Proposed mechanisms for the exact pathophysiology of this include molecular mimicry between the SARS-CoV-2 spike protein and cardiac antigens, activation of immune pathways, and dysregulated cytokine expression. Despite these findings, the overall benefit-risk balance for COVID-19 vaccination remains positive, as the majority of patients recover fully. In contrast, COVID-19-associated myocarditis is more common and more severe, with an estimated incidence of 1,000-1,400 cases per 100,000 infections. Clinical presentation of vaccine-associated myocarditis is usually mild and self-limiting, and most patients do recover without significant long-term effects. Treatment is usually supportive in nature and has an emphasis on ruling out acute coronary syndrome and symptomatic management for heart failure or arrhythmias if present. Given its low incidence and the generally good outcome, vaccination against COVID-19 is recommended from 12 years of age and above, with provision for ongoing surveillance for monitoring and management of rare adverse events like myocarditis.

Keywords : Myocarditis, COVID-19, Vaccination, mRNA Vaccine.

References :

1. H. Cheng et al., “Efficacy and Safety of COVID-19 vaccines in Phase III trials: A Meta-Analysis,” Vaccines, vol. 9, no. 6, p. 582, Jun. 2021, doi: 10.3390/vaccines9060582.
2. L. R. Baden et al., “Efficacy and safety of the mRNA-1273 SARS-COV-2 vaccine,” New England Journal of Medicine, vol. 384, no. 5, pp. 403–416, Feb. 2021, doi: 10.1056/nejmoa2035389.
3. J. Pillay et al., “Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review,” BMJ, p. e069445, Jul. 2022, doi: 10.1136/bmj-2021-069445.
4. Roth GA  et al., “Correction,” Journal of the American College of Cardiology, vol. 77, no. 15, pp. 1958–1959, Apr. 2021, doi: 10.1016/j.jacc.2021.02.039.
5. R. K. Wadhera, C. Shen, S. Gondi, S. Chen, D. S. Kazi, and R. W. Yeh, “Cardiovascular deaths during the COVID-19 pandemic in the United States,” Journal of the American College of Cardiology, vol. 77, no. 2, pp. 159–169, Jan. 2021, doi: 10.1016/j.jacc.2020.10.055.
6. E. Kontopantelis et al., “Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study,” The Lancet Regional Health - Europe, vol. 7, p. 100144, Aug. 2021, doi: 10.1016/j.lanepe.2021.100144.
7. D. Patriki, J. Kottwitz, J. Berg, U. Landmesser, T. F. Lüscher, and B. Heidecker, “Clinical Presentation and Laboratory Findings in Men Versus Women with Myocarditis,” Journal of Women S Health, vol. 29, no. 2, pp. 193–199, Feb. 2020, doi: 10.1089/jwh.2018.7618.
8. D. Mevorach et al., “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,” New England Journal of Medicine, vol. 385, no. 23, pp. 2140–2149, Dec. 2021, doi: 10.1056/nejmoa2109730.
9. N. P. Klein et al., “Surveillance for adverse events after COVID-19 mRNA vaccination,” JAMA, vol. 326, no. 14, p. 1390, Oct. 2021, doi: 10.1001/jama.2021.15072.
10. J. Montgomery et al., “Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military,” JAMA Cardiology, vol. 6, no. 10, p. 1202, Oct. 2021, doi: 10.1001/jamacardio.2021.2833.
11. S. Greulich et al., “Predictors of Mortality in Patients with Biopsy‐Proven Viral Myocarditis: 10‐Year Outcome data,” Journal of the American Heart Association, vol. 9, no. 16, Aug. 2020, doi: 10.1161/jaha.119.015351.
12. P. E. Tam, “Coxsackievirus Myocarditis: Interplay between Virus and Host in the Pathogenesis of Heart Disease,” Viral Immunology, vol. 19, no. 2, pp. 133–146, Jun. 2006, doi: 10.1089/vim.2006.19.133.
13. C. B. Coyne and J. M. Bergelson, “Virus-Induced Abl and Fyn Kinase Signals Permit Coxsackievirus Entry through Epithelial Tight Junctions,” Cell, vol. 124, no. 1, pp. 119–131, Jan. 2006, doi: 10.1016/j.cell.2005.10.035.
14. P. Schmerler et al., “Mortality and morbidity in different immunization protocols for experimental autoimmune myocarditis in rats,” Acta Physiologica, vol. 210, no. 4, pp. 889–898, Feb. 2014, doi: 10.1111/apha.12227.
15. X. Clemente-Casares et al., “A CD103+ Conventional Dendritic Cell Surveillance System Prevents Development of Overt Heart Failure during Subclinical Viral Myocarditis,” Immunity, vol. 47, no. 5, pp. 974-989.e8, Nov. 2017, doi: 10.1016/j.immuni.2017.10.011.
16. D. Zehn and M. J. Bevan, “T Cells with Low Avidity for a Tissue-Restricted Antigen Routinely Evade Central and Peripheral Tolerance and Cause Autoimmunity,” Immunity, vol. 25, no. 2, pp. 261–270, Aug. 2006, doi: 10.1016/j.immuni.2006.06.009.
17. Y. Li et al., “Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy,” Circulation, vol. 101, no. 3, pp. 231–234, Jan. 2000, doi: 10.1161/01.cir.101.3.231.
18. F. Caso et al., “Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?,” Autoimmunity Reviews, vol. 19, no. 5, p. 102524, May 2020, doi: 10.1016/j.autrev.2020.102524.
19. M. Fraser et al., “COVID-19-Associated myocarditis: an evolving concern in cardiology and beyond,” Biology, vol. 11, no. 4, p. 520, Mar. 2022, doi: 10.3390/biology11040520.
20. H. R. Figulla, “Transformation of myocarditis and inflammatory cardiomyopathy to idiopathic dilated cardiomyopathy: facts and fiction,” Medical Microbiology and Immunology, vol. 193, no. 2–3, pp. 61–64, May 2004, doi: 10.1007/s00430-003-0205-y.
21. S. Heymans, U. Eriksson, J. Lehtonen, and L. T. Cooper, “The quest for new approaches in myocarditis and inflammatory cardiomyopathy,” Journal of the American College of Cardiology, vol. 68, no. 21, pp. 2348–2364, Nov. 2016, doi: 10.1016/j.jacc.2016.09.937.
22. M. Müller, L. T. Cooper, and B. Heidecker, “Diagnosis, risk stratification and management of myocarditis,” Heart, vol. 108, no. 18, pp. 1486–1497, Dec. 2021, doi: 10.1136/heartjnl-2021-319027.
23. W. Woo et al., “Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine,” Journal of Medical Virology, vol. 94, no. 4, pp. 1566–1580, Dec. 2021, doi: 10.1002/jmv.27501.
24. M. E. Oster et al., “Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021,” JAMA, vol. 327, no. 4, p. 331, Jan. 2022, doi: 10.1001/jama.2021.24110.
25. M. Gnecchi et al., “Myocarditis in a 16-year-old boy positive for SARS-CoV-2,” The Lancet, vol. 395, no. 10242, p. e116, Jun. 2020, doi: 10.1016/s0140-6736(20)31307-6.
26. A. K. Verma, K. J. Lavine, and C.-Y. Lin, “Myocarditis after Covid-19 mRNA Vaccination,” New England Journal of Medicine, vol. 385, no. 14, pp. 1332–1334, Sep. 2021, doi: 10.1056/nejmc2109975.
27. L. T. Cooper, “Myocarditis,” New England Journal of Medicine, vol. 360, no. 15, pp. 1526–1538, Apr. 2009, doi: 10.1056/nejmra0800028.
28. E. Saricam, Y. Saglam, and T. Hazirolan, “Clinical evaluation of myocardial involvement in acute myopericarditis in young adults,” BMC Cardiovascular Disorders, vol. 17, no. 1, May 2017, doi: 10.1186/s12872-017-0564-8.
29. H. R. Figulla, “Transformation of myocarditis and inflammatory cardiomyopathy to idiopathic dilated cardiomyopathy: facts and fiction,” Medical Microbiology and Immunology, vol. 193, no. 2–3, pp. 61–64, May 2004, doi: 10.1007/s00430-003-0205-y.
30. C. Costa and F. Moniati, “The Epidemiology of COVID-19 Vaccine-Induced Myocarditis,” Advances in Medicine, vol. 2024, pp. 1–17, Apr. 2024, doi: 10.1155/2024/4470326.
31. R. J. Benschop et al., “The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination,” medRxiv (Cold Spring Harbor Laboratory), Dec. 2021, doi: 10.1101/2021.12.15.21267605.
32. T. K. Boehmer et al., “Association between COVID-19 and myocarditis using Hospital-Based Administrative Data — United States, March 2020–January 2021,” MMWR Morbidity and Mortality Weekly Report, vol. 70, no. 35, pp. 1228–1232, Sep. 2021, doi: 10.15585/mmwr.mm7035e5.
33. D. Bojkova et al., “SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes,” Cardiovascular Research, vol. 116, no. 14, pp. 2207–2215, Sep. 2020, doi: 10.1093/cvr/cvaa267.
34. T. A. McDonagh et al., “Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 42, no. 48, p. 4901, Oct. 2021, doi: 10.1093/eurheartj/ehab670.
35. “Corrigendum to: ‘A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Registry’ and articles listed below,” European Journal of Heart Failure, vol. 25, no. 3, p. 443, Feb. 2023, doi: 10.1002/ejhf.2789.
36. R. D. Kociol et al., “Recognition and initial management of fulminant myocarditis,” Circulation, vol. 141, no. 6, Feb. 2020, doi: 10.1161/cir.0000000000000745.
37. F. Ceban et al., “COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis,” Brain Behavior and Immunity, vol. 111, pp. 211–229, Jul. 2023, doi: 10.1016/j.bbi.2023.03.022.
38. B. Raman, D. A. Bluemke, T. F. Lüscher, and S. Neubauer, “Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus,” European Heart Journal, vol. 43, no. 11, pp. 1157–1172, Feb. 2022, doi: 10.1093/eurheartj/ehac031.
39. R. R. Ling et al., “Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis,” The Lancet Respiratory Medicine, vol. 10, no. 7, pp. 679–688, Jul. 2022, doi: 10.1016/s2213-2600(22)00059-5.
40. M. Marshall et al., “Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination,” PEDIATRICS, vol. 148, no. 3, Sep. 2021, doi: 10.1542/peds.2021-052478.
41. D. K. Shay, T. T. Shimabukuro, and F. DeStefano, “Myocarditis occurring after immunization with mRNA-Based COVID-19 vaccines,” JAMA Cardiology, vol. 6, no. 10, p. 1115, Oct. 2021, doi: 10.1001/jamacardio.2021.2821.
42. K.-H. Son, S.-H. Kwon, H.-J. Na, Y. Baek, I. Kim, and E.-K. Lee, “Quantitative Benefit–Risk Assessment of COVID-19 vaccines using the Multi-Criteria Decision Analysis,” Vaccines, vol. 10, no. 12, p. 2029, Nov. 2022, doi: 10.3390/vaccines10122029.
43. M. Wallace et al., “A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States,” Vaccine, vol. 41, no. 44, pp. 6456–6467, Oct. 2023, doi: 10.1016/j.vaccine.2023.07.037.
44. J. R. Su et al., “Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018,” Vaccine, vol. 39, no. 5, pp. 839–845, Jan. 2021, doi: 10.1016/j.vaccine.2020.12.046.
45. B. Bozkurt, I. Kamat, and P. J. Hotez, “Myocarditis with COVID-19 mRNA vaccines,” Circulation, vol. 144, no. 6, pp. 471–484, Aug. 2021, doi: 10.1161/circulationaha.121.056135.